Analysts Set $6.38 Price Target for Aevi Genomic Medicine, Inc. (GNMX)
Shares of Aevi Genomic Medicine, Inc. (NASDAQ:GNMX) have been given an average broker rating score of 2.00 (Buy) from the three brokers that provide coverage for the company, Zacks Investment Research reports. One equities research analyst has rated the stock with a hold rating, one has given a buy rating and one has given a strong buy rating to the company. Aevi Genomic Medicine’s rating score has declined by 14.3% from 90 days ago as a result of a number of analysts’ ratings changes.
Brokers have set a twelve-month consensus price objective of $6.38 for the company and are predicting that the company will post ($0.17) earnings per share for the current quarter, according to Zacks. Zacks has also given Aevi Genomic Medicine an industry rank of 220 out of 265 based on the ratings given to related companies.
A number of equities analysts recently commented on GNMX shares. Jefferies Group reiterated a “hold” rating and set a $1.50 target price on shares of Aevi Genomic Medicine in a research note on Thursday, September 28th. Needham & Company LLC decreased their price objective on shares of Aevi Genomic Medicine from $9.00 to $7.00 and set a “buy” rating for the company in a research note on Wednesday, August 16th.
Several hedge funds have recently added to or reduced their stakes in the company. TIAA CREF Investment Management LLC grew its position in shares of Aevi Genomic Medicine by 16.7% in the first quarter. TIAA CREF Investment Management LLC now owns 97,719 shares of the biotechnology company’s stock valued at $182,000 after purchasing an additional 13,966 shares during the last quarter. Northern Capital Management LLC grew its position in shares of Aevi Genomic Medicine by 43.6% in the third quarter. Northern Capital Management LLC now owns 152,300 shares of the biotechnology company’s stock valued at $192,000 after purchasing an additional 46,250 shares during the last quarter. Birchview Capital LP grew its position in shares of Aevi Genomic Medicine by 88.2% in the second quarter. Birchview Capital LP now owns 128,000 shares of the biotechnology company’s stock valued at $170,000 after purchasing an additional 60,000 shares during the last quarter. Wells Fargo & Company MN boosted its position in Aevi Genomic Medicine by 433.7% during the third quarter. Wells Fargo & Company MN now owns 130,662 shares of the biotechnology company’s stock worth $165,000 after acquiring an additional 106,178 shares during the last quarter. Finally, LMR Partners LLP acquired a new stake in Aevi Genomic Medicine during the second quarter worth approximately $149,000. Institutional investors and hedge funds own 16.90% of the company’s stock.
Aevi Genomic Medicine (NASDAQ:GNMX) traded up $0.04 during trading on Friday, hitting $1.21. The stock had a trading volume of 1,106,600 shares, compared to its average volume of 481,302. Aevi Genomic Medicine has a 1-year low of $0.98 and a 1-year high of $6.89.
Aevi Genomic Medicine (NASDAQ:GNMX) last issued its earnings results on Thursday, November 2nd. The biotechnology company reported ($0.23) EPS for the quarter, missing analysts’ consensus estimates of ($0.22) by ($0.01). During the same period in the previous year, the business posted ($0.29) EPS. research analysts forecast that Aevi Genomic Medicine will post -0.88 EPS for the current fiscal year.
TRADEMARK VIOLATION NOTICE: “Analysts Set $6.38 Price Target for Aevi Genomic Medicine, Inc. (GNMX)” was originally reported by American Banking News and is owned by of American Banking News. If you are viewing this piece on another publication, it was illegally stolen and republished in violation of U.S. and international copyright and trademark law. The correct version of this piece can be viewed at https://www.americanbankingnews.com/2017/12/01/analysts-set-6-38-price-target-for-aevi-genomic-medicine-inc-gnmx.html.
Aevi Genomic Medicine Company Profile
Aevi Genomic Medicine, Inc, a clinical stage biopharmaceutical company, researches and develops novel therapies for pediatric onset and life-altering diseases in the United States. Its lead product candidates include AEVI-001, a glutamatergic neuromodulator, which is in Phase II/III SAGA trial for a genetically-defined subset of adolescent attention deficit hyperactivity disorder patients with specific mutations in their metabotropic glutamate receptor gene network; and AEVI-002, an anti-light monoclonal antibody that is in Phase I clinical trial for use in severe pediatric onset crohns disease.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Aevi Genomic Medicine Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aevi Genomic Medicine Inc. and related companies with MarketBeat.com's FREE daily email newsletter.